Symbols

SVRA

Savara·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 0

Ample Liquidity

Gap Up

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SVRA

Savara Inc.

A biopharmaceutical company that develops and commercializes therapies for rare respiratory diseases

Industry

Biological Technology

Established Date

Listing Date

04/28/2017

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.savarapharma.com

Security Type

Common stock

Office address

1717 Langhorne Newtown Road, Suite 300 Langhorne, Pennsylvania 19047

Business

Introduction

Savara Inc., was incorporated in Delaware in December 1995. The company is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Its only program, molgramostim inhalation solution (MOLBREEVI), is an investigational inhaled biologic that is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis and has received Fast Track, Breakthrough Therapy and Orphan Drug designation.

Company Financials

EPS

SVRA has released its 2025 Q4 earnings. EPS was reported at -0.13, versus the expected -0.12, missing expectations. The chart below visualizes how SVRA has performed over recent quarters, highlighting trends in earnings surprises.